迈瑞医疗官宣H股上市计划：董事会已通过议案

Core Viewpoint - Mindray Medical has announced plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and capital strength [2][3] Group 1: Listing Plans - The company aims to establish an "A+H" dual capital market structure to support its business development and internationalization strategy [3] - The listing process will consider the interests of existing shareholders and market conditions, with a timeline of 24 months from shareholder approval [3] - The issuance and listing require multiple approvals from regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [3] Group 2: Strategic Timing - Mindray Medical believes the current market environment in Hong Kong is favorable for high-quality leading assets, making it an opportune time for international capital operations [3] Group 3: Fund Utilization - Proceeds from the H-share issuance will be used for advancing international strategy, increasing R&D investment, and supplementing operational funds [4] - The company may consider using capital market financing for acquisitions if suitable overseas targets arise, aligning with its strategic planning [4] Group 4: International Business Growth - As of the 2025 semi-annual report, international business revenue reached 8.33 billion yuan, accounting for over 50% of total revenue [4] - Mindray has established localized production in 14 countries, with operations initiated in 11 countries and over 210 high-end overseas clients [4] - The management anticipates sustained rapid growth in international markets, particularly in developing countries where market capacity is comparable to China [5]